Call Now Open
2026 Oxford-Harrington Rare Disease Scholar Award
February 28, 2026
Op-Ed Authored by Lord (David) Cameron, former UK Prime Minister and Chair of the OHC Advisory Council published in The Daily Telegraph on Saturday, Feb. 28, 2026 (Rare Disease Day) Rare diseases are not actually that rare. Collectively they affect 500 million people around the world. Some, such as Huntington’s disease...
Continue Reading
February 26, 2026
The Oxford-Harrington Rare Disease Centre (OHC) highlights its commitment to driving progress for rare disease—impacting the lives of families like Cynthia Schulz and her daughter Noni who spent decades living answers or effective treatments for CASK Continue Reading
February 06, 2026
Harrington Discovery Institute at University Hospitals is supporting the development of a new drug called Zalunfiban that helped thousands of heart attack patients avoid complications in clinical trials. Continue Reading
January 29, 2026
Oxford-Harrington Rare Disease Centre operates a transatlantic model that embeds industry expertise directly into academic rare disease programs. $250 Million Committed to Advance 40 Therapies into Clinical Trials by 2034 Continue Reading
January 15, 2026
Prestigious Scholar Award Accelerates Novel Therapies for Patients with Rare Diseases Continue Reading
December 23, 2025
New Study from University Hospitals and Case Western Reserve University published in Science Signaling Continue Reading
December 23, 2025
A conversation with Matthew P. Anderson, MD, Ph.D., co-director, Oxford-Harrington Rare Disease Centre, featured in Drug Discovery Online Continue Reading
December 22, 2025
For over a century, Alzheimer's disease (AD) has been considered irreversible. Consequently, research has focused on disease prevention or slowing, rather than recovery. Despite billions of dollars spent on decades of research, there has never been a clinical trial of a drug for AD with an outcome goal of reversing disease and... Continue Reading
December 16, 2025
Despite the central role of p53 suppression in cancer pathogenesis, the promise of therapeutic p53 reactivation remains unrealized, with targeted and combination chemotherapies limited by efficacy, toxicity, and delivery. Continue Reading
November 20, 2025
Ten scientists selected for second annual award to pursue innovations in gene, RNA, small molecule and cell therapies to treat rare and ultra-rare diseases Continue Reading
November 14, 2025
Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and other devastating autoimmune diseases — by reprogramming patients’ out-of-whack immune systems. Continue Reading